Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020102731 - ALS TREATMENT USING INDUCED REGULATORY T (iTREG) CELLS

Publication Number WO/2020/102731
Publication Date 22.05.2020
International Application No. PCT/US2019/061818
International Filing Date 15.11.2019
IPC
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Applicants
  • RAPA THERAPEUTICS, LLC [US]/[US]
Inventors
  • FOWLER, Daniel, Harding
Agents
  • COX, Ryan, P.
Priority Data
62/768,17616.11.2018US
62/927,07528.10.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ALS TREATMENT USING INDUCED REGULATORY T (iTREG) CELLS
(FR) TRAITEMENT DE SLA À L'AIDE DE LYMPHOCYTES T (ITREG) RÉGULATEURS INDUITS
Abstract
(EN)
The present disclosure provides methods for treating ALS using pentostatin and cyclophosphamide treatment followed by TREG and/or TREG/Th2 hybrid cells from dedifferentiated T cells. The present disclosure further provides methods for producing TREG and TREG/Th2 hybrid cells from de-differentiated T cells, said TREG and TREG/Th2 hybrid cells, populations thereof and compositions thereof. Methods for producing de-differentiated T cells, said de-differentiated T cells, populations thereof and compositions thereof are also provided.
(FR)
La présente invention concerne des méthodes de traitement de la SLA au moyen d'un traitement avec de la pentostatine et du cyclophosphamide suivi par des cellules TREG et/ou des cellules hybrides TREG/Th2 provenant de lymphocytes T dédifférenciés. La présente invention concerne également des procédés de production de cellules TREG et de cellules hybrides TREG/Th2 à partir de lymphocytes T dédifférenciés, lesdites cellules TREG et cellules hybrides TREG/Th2, leurs populations et leurs compositions. L'invention concerne également des procédés de production de lymphocytes T dédifférenciés, lesdits lymphocytes T dédifférenciés, des populations de ceux-ci et des compositions de ceux-ci.
Latest bibliographic data on file with the International Bureau